List of Chapters/Sections(Table Of Content)
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hereditary Angioedema Revenue
1.4 Market Analysis by Type
1.4.1 Global Hereditary Angioedema Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 C1 Esterase Inhibitor
1.4.3 Kallikrein Inhibitor
1.4.4 Selective Bradykinin B2 Receptor Antagonist
1.5 Market by Application
1.5.1 Global Hereditary Angioedema Market Share by Application: 2022-2027
1.5.2 Retail Pharmacies
1.5.3 Hospital Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Hereditary Angioedema Market
1.8.1 Global Hereditary Angioedema Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Hereditary Angioedema Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Hereditary Angioedema Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Hereditary Angioedema Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Hereditary Angioedema Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Hereditary Angioedema Sales Volume Market Share by Region (2016-2021)
3.2 Global Hereditary Angioedema Sales Revenue Market Share by Region (2016-2021)
3.3 North America Hereditary Angioedema Sales Volume
3.3.1 North America Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.3.2 North America Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Hereditary Angioedema Sales Volume
3.4.1 East Asia Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Hereditary Angioedema Sales Volume (2016-2021)
3.5.1 Europe Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Hereditary Angioedema Sales Volume (2016-2021)
3.6.1 South Asia Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Hereditary Angioedema Sales Volume (2016-2021)
3.7.1 Southeast Asia Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Hereditary Angioedema Sales Volume (2016-2021)
3.8.1 Middle East Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Hereditary Angioedema Sales Volume (2016-2021)
3.9.1 Africa Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Hereditary Angioedema Sales Volume (2016-2021)
3.10.1 Oceania Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Hereditary Angioedema Sales Volume (2016-2021)
3.11.1 South America Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.11.2 South America Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Hereditary Angioedema Sales Volume (2016-2021)
3.12.1 Rest of the World Hereditary Angioedema Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Hereditary Angioedema Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Hereditary Angioedema Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Hereditary Angioedema Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Hereditary Angioedema Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Hereditary Angioedema Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Hereditary Angioedema Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Hereditary Angioedema Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Hereditary Angioedema Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Hereditary Angioedema Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Hereditary Angioedema Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Hereditary Angioedema Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Hereditary Angioedema Sales Volume Market Share by Type (2016-2021)
14.2 Global Hereditary Angioedema Sales Revenue Market Share by Type (2016-2021)
14.3 Global Hereditary Angioedema Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Hereditary Angioedema Consumption Volume by Application (2016-2021)
15.2 Global Hereditary Angioedema Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Hereditary Angioedema Business
16.1 Pharming Group NV
16.1.1 Pharming Group NV Company Profile
16.1.2 Pharming Group NV Hereditary Angioedema Product Specification
16.1.3 Pharming Group NV Hereditary Angioedema Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Takeda
16.2.1 Takeda Company Profile
16.2.2 Takeda Hereditary Angioedema Product Specification
16.2.3 Takeda Hereditary Angioedema Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 CSL Limited
16.3.1 CSL Limited Company Profile
16.3.2 CSL Limited Hereditary Angioedema Product Specification
16.3.3 CSL Limited Hereditary Angioedema Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 iBio Inc.
16.4.1 iBio Inc. Company Profile
16.4.2 iBio Inc. Hereditary Angioedema Product Specification
16.4.3 iBio Inc. Hereditary Angioedema Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 BioCryst Pharmaceuticals, Inc.
16.5.1 BioCryst Pharmaceuticals, Inc. Company Profile
16.5.2 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Product Specification
16.5.3 BioCryst Pharmaceuticals, Inc. Hereditary Angioedema Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Ionis Pharmaceuticals, Inc.
16.6.1 Ionis Pharmaceuticals, Inc. Company Profile
16.6.2 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Product Specification
16.6.3 Ionis Pharmaceuticals, Inc. Hereditary Angioedema Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Hereditary Angioedema Manufacturing Cost Analysis
17.1 Hereditary Angioedema Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Hereditary Angioedema
17.4 Hereditary Angioedema Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Hereditary Angioedema Distributors List
18.3 Hereditary Angioedema Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Hereditary Angioedema (2022-2027)
20.2 Global Forecasted Revenue of Hereditary Angioedema (2022-2027)
20.3 Global Forecasted Price of Hereditary Angioedema (2016-2027)
20.4 Global Forecasted Production of Hereditary Angioedema by Region (2022-2027)
20.4.1 North America Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.3 Europe Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.7 Africa Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.9 South America Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Hereditary Angioedema Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Hereditary Angioedema by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Hereditary Angioedema by Country
21.2 East Asia Market Forecasted Consumption of Hereditary Angioedema by Country
21.3 Europe Market Forecasted Consumption of Hereditary Angioedema by Countriy
21.4 South Asia Forecasted Consumption of Hereditary Angioedema by Country
21.5 Southeast Asia Forecasted Consumption of Hereditary Angioedema by Country
21.6 Middle East Forecasted Consumption of Hereditary Angioedema by Country
21.7 Africa Forecasted Consumption of Hereditary Angioedema by Country
21.8 Oceania Forecasted Consumption of Hereditary Angioedema by Country
21.9 South America Forecasted Consumption of Hereditary Angioedema by Country
21.10 Rest of the world Forecasted Consumption of Hereditary Angioedema by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
